
Inhibrx INBX
$ 129.21
3.52%
Annual report 2023
added 02-28-2024
Inhibrx Total Current Liabilities 2011-2026 | INBX
Annual Total Current Liabilities Inhibrx
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 56.3 M | 27.6 M | 22.5 M | 31.4 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 56.3 M | 22.5 M | 34.4 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
4.59 M | $ 0.88 | -1.69 % | $ 6.47 M | ||
|
Aquestive Therapeutics
AQST
|
47.6 M | $ 4.1 | 1.23 % | $ 438 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
395 M | $ 22.45 | 1.13 % | $ 3.72 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
47.5 M | - | - | $ 269 M | ||
|
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
16.3 M | - | -11.76 % | $ 5.79 M | ||
|
Berkeley Lights
BLI
|
45.5 M | - | -7.31 % | $ 87 M | ||
|
Calithera Biosciences
CALA
|
14 M | - | -10.95 % | $ 876 K | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
CymaBay Therapeutics
CBAY
|
36.8 M | - | - | $ 3.45 B | ||
|
ChemoCentryx
CCXI
|
63 M | - | - | $ 3.74 B | ||
|
Cerus Corporation
CERS
|
101 M | $ 2.03 | 5.73 % | $ 387 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Caladrius Biosciences
CLBS
|
5.61 M | - | -16.75 % | $ 25.8 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
100 M | - | - | $ 2.18 B | ||
|
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | ||
|
Dynavax Technologies Corporation
DVAX
|
78.6 M | - | - | $ 2.02 B | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | ||
|
Editas Medicine
EDIT
|
46.2 M | $ 3.0 | 6.38 % | $ 266 M | ||
|
Edesa Biotech
EDSA
|
1.83 M | $ 18.27 | 14.94 % | $ 58.4 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 3.19 | 6.69 % | $ 5.25 M | ||
|
Eiger BioPharmaceuticals
EIGR
|
53.3 M | - | -9.21 % | $ 2.55 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
23.1 M | - | -5.68 % | $ 8.28 M | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | ||
|
Applied Therapeutics
APLT
|
71.2 M | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
22.1 M | - | -13.39 % | $ 1.45 M |